The DSHEA Disclaimer Does Not Save a Diabetes Ad

what does ftc example 47 describe step by step?

Example 47 walks through a single hypothetical ad step by step: an herbal supplement, an unqualified claim that the product treats diabetes, no adequate substantiation behind that claim, and a DSHEA disclaimer sitting prominently on the page anyway.

FTC's own guidance concludes that "the inclusion of the DSHEA disclaimer doesn't negate the explicit and directly contradictory claim that the product treats diabetes." We read the full diabetes section of the December 2022 guidance to confirm Example 47 sits there rather than being borrowed from another vertical, and it does.

The disclaimer changed nothing, because the claim it sat beside was never eligible for one.

We compared the wording of Examples 14, 15 and 47 side by side, and the underlying logic is identical across all three: a claim, a disclaimer, and a finding that the two don't cancel out.

why does a prominent disclaimer fail against a contradictory claim?

A prominent disclaimer fails once the claim beside it is a disease claim, because the disclaimer is built to accompany a lawful statement — it has no legal work to do next to an unlawful one. Under 21 CFR 101.93(f), the disclaimer only ever modifies a structure/function claim; if the sentence beside it names a disease and promises to treat it, that sentence was never eligible for the disclaimer's protection in the first place.

Boldface type and box placement satisfy the disclaimer's own formatting rules, but neither rule has jurisdiction over whether the sentence next to it was lawful to begin with. A regulator reading the page asks a different question first — is this a disease claim, full stop — and if it is, no amount of correct disclaimer formatting changes the answer.

Media buyers who study a rival's landing page for cues on how big a disclaimer 'needs to be' are chasing the wrong variable. Box size was never what mattered, and the same substance-over-form test comes up when you're deciding whether it's legal to copy a competitor's ad rather than just its layout.

what does example 14 add about directly contradictory disclaimers?

Example 14 confirms the same doctrine outside dietary supplements entirely. An app claimed to treat acne while carrying the line 'This app is for entertainment purposes only and is not intended for the treatment of any disease or medical condition,' and FTC found the disclaimer 'directly contradictory and ineffective to negate the acne treatment claim.'

An entertainment disclaimer sitting next to a claim of medical treatment contradicts itself before any regulator has to argue the point, and that's precisely why Example 14 matters beyond acne. FTC applies the same contradiction test to a wellness app, a supplement, or a device, regardless of medium. Compliance teams that pull competitor pages to benchmark disclaimer wording sometimes do that research through scraping tools built to avoid detection, a separate legal question covered in are antidetect browsers legal for ad research — but the contradiction test itself doesn't care how the page was retrieved.

how did example 15 treat fine print buried in terms and conditions?

Example 15 treated a line reading 'no clinical study has been performed,' buried in the site's Terms and Conditions, as no cure at all for a headline claim of scientific proof built on lab coats and medical terminology. The disclosure was accurate, but fine print a shopper will never scroll to doesn't count as disclosure no matter how true it is.

We could not verify whether FTC has applied Example 15's exact reasoning inside a diabetes-specific enforcement matter — the guidance places the example in its weight-loss discussion, not its diabetes section, and cites no underlying case name to check against. What would settle it is a search of FTC's litigated complaints for a comparable buried-disclosure fact pattern paired with a disease-specific health claim.

what is the disclaimer actually for under 21 cfr 101.93(c)?

Under 21 CFR 101.93(c), the disclaimer's job is narrow: it exists to flag a lawful structure/function claim, not to rescue an unlawful disease claim. FDA fixed the exact wording — the regulation requires: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."

The regulation surrounds that sentence with placement rules most advertisers never read past the wording itself. Under 101.93(d), the disclaimer must sit adjacent to the claim with no intervening material, or be linked to it by a symbol such as an asterisk, and it must appear on every panel or page where the claim itself appears — not once, buried, at the bottom of a long page. Under 101.93(e), the text must run in boldface type no smaller than one-sixteenth of an inch, which rules out the faint gray footer text common on affiliate landing pages. And under 101.93(a), the manufacturer, packer or distributor carrying the claim must notify FDA's Office of Dietary Supplement Programs within 30 days of first marketing, a certification step that has nothing to do with whether the underlying claim is true.

None of that machinery has any authority over a sentence that names a disease.

when does a disclosure work rather than merely appear?

A disclosure works when it sits at the same size and in the same place as the claim it qualifies, and states what the evidence actually showed rather than disclaiming your responsibility for it. FTC's guidance shows the fix directly: for a testimonial claiming 16 pounds lost in eight weeks against a study averaging only 4 pounds over placebo, the prescribed remedy is a prominent, adjacent statement of the actual study average — not the phrase 'results not typical' tucked into a footnote.

Proximity and size do the legal work that a disclaimer's mere existence never can, and the same principle shows up outside nutra entirely — a disclaimer can't cure a claim it contradicts, whichever vertical is running the ad. Advertisers moving between health and other regulated categories learn this the hard way when jurisdiction, not wording, decides what's even sellable, the same lesson that runs through gambling offers in 2026: where advertising is legal.

The same guidance runs the duty in the other direction too: even where no health claim is made at all, FTC's Example 10 says a known safety risk — such as an ingredient that raises blood pressure with daily long-term use — should be disclosed on its own, independent of what the rest of the ad claims. Silence can be exactly as deceptive as a contradicted disclaimer.

what would need to change for the ad in example 47 to survive?

For the ad in Example 47 to survive, one of two things would have to change, and only one is realistic. The hard path is substantiation: FTC's guidance states that 'substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing,' a bar almost no supplement trial clears for a disease-treatment claim. The workable path is dropping the disease claim and rewriting toward FDA's one blessed sentence for this exact vertical.

FDA drafted exactly this fork for blood-sugar copy. A supplement instructed for use alongside insulin to help maintain a healthy blood sugar level is a disease claim, because tying the product to insulin ties it to the disease insulin treats. Delete the reference to insulin, per FDA's own reasoning, and the identical sentence stops implying diabetes treatment altogether.

Either way, the fix has to happen well before the disclaimer question ever comes up, because by the time you're arguing over boldface size, the underlying sentence has already decided the outcome.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Insomnia in a Bundle Is Still a Drug Claim, Ingredient Studies Do Not Substantiate Your Formula, Occasional Constipation Is Allowed, With a Condition, Their Blog Posts Became the Drug Evidence, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.